Intellia R&D head says new gene-editing data shows path to human trials – Boston Business Journal


Boston Business Journal
Intellia R&D head says new gene-editing data shows path to human trials
Boston Business Journal
Cambridge-based Intellia Therapeutics had the biggest IPO of any local biotech in 2016, but shares of the company have lagged in recent months, and it has often been overshadowed by its gene-editing rival in Kendall Square, Editas Medicine.

and more »

Continue reading here:
Intellia R&D head says new gene-editing data shows path to human trials - Boston Business Journal

Related Posts

Comments are closed.